Answers are grounded in this paper and cite their sources.
In this study, to identify novel compounds that inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication by targeting its protease, we screened an U.S. Food and Drug Administration (FDA)-approved drug library to determine their effects on SARS-CoV-2 3CL protease (3CLpro) activity using a cellular- and green fluorescent protein (GFP) reporter-based 3CLpro assay, called the FlipGFP-3CLpro assay. Among the hit compounds, 5 compounds (auranofin, endoxifen, netupitant, pimozide, and regorafenib) were selected for further analysis. We found that 3 compounds (auranofin, endoxifen, and pimozide) showed dose-dependent inhibition of 3CLpro activity using both the FlipGFP-3CLpro assay and fluorescence-based in vitro 3CLpro assays. We then tested the effect of these compounds on SARS-CoV-2 replication in cultured cells and found that all 5 compounds inhibited viral replication in a dose-dependent manner. Interestingly, 4 of them, except for auranofin, significantly suppressed human norovirus (HuNoV) replication in human intestinal organoids. In brief, we identified several FDA-approved drugs that inhibit SARS-CoV-2 and HuNoV replication, which warrant further investigation.
No takes yet. Share an insight, caveat, or question.
Hayashi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: